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• Potent newer-generation adenosine diphosphate receptor antagonists (prasugrel and ticagrelor) reduce major cardiovascular events in comparison with clopidogrel but are also associated with an increase in major bleeding.
• Use of glycoprotein IIb/IIIa inhibitors is mostly limited to the catheterization laboratory setting for procedural complications.
• Patients undergoing invasive management should receive intravenous unfractionated heparin, preferably with bivalirudin at the time of percutaneous coronary intervention.
• Patients receiving medical management (including those receiving fibrinolytics) should be given either enoxaparin or fondaparinux subcutaneously.
• In general, full dose oral anticoagulants are not indicated after acute coronary syndrome and warfarin should be the preferred agent in patients with other indications for anticoagulation such as atrial fibrillation or thromboembolic disease.
What additional antiplatelet therapy should be given?
In addition to ASA, patients with acute coronary syndrome benefit from further inhibition of platelet aggregation by adenosine diphosphate (ADP) P2Y12 receptor antagonists. Until recently, only 2 agents were available: clopidogrel and ticlopidine, with ticlopidine usually reserved for patients with intolerance to clopidogrel. Major advances were made to antiplatelet therapy with the approval of 2 new agents, prasugrel and ticagrelor, which both have a more rapid, predictable and potent antiplatelet effect than clopidogrel (Table 1) .
Clopidogrel
Clopidogrel has been extensively studied and has a class I recommendation (i.e., evidence or general agreement that treatment is useful and effective) for 1 year of treatment irrespective of invasive or conservative management of acute coronary syndrome. [13] [14] [15] [16] [17] In situations where rapid onset of action is needed, a 600-mg loading dose of clopidogrel was shown to be faster acting than the usual 300-mg loading dose. 18 Researchers attempted to address clopidogrel hyporesponsiveness by testing a double-dosing regimen during the first week in the CURRENT-OASIS 7 trial. 7 This regimen was not associated with a decrease in major cardiovascular events in the overall cohort; however, in the subgroup of patients who underwent PCI, major cardiovascular events at 30 days decreased from 4.5% to 3.9% (HR 0.86, 95% CI 0.74-0.99) with an increase in severe bleeding from 1.1% to 1.6% (HR 1.41, 95% CI 1.09-1.83). 12 Observational studies also raised the possibility that a drug-drug interaction with proton pump inhibitors might partially explain the variability in responsiveness to clopidogrel. 19, 20 However, the only RCT that tested the addition of omeprazole among patients receiving ASA and clopidogrel, COGENT (the Clopidogrel and the Optimization of Gastrointestinal Events Trial), showed no difference in major cardiovascular events at 6 months. 21 
Prasugrel
In TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38), researchers studied the use of prasugrel among patients with acute coronary syndrome who were undergoing PCI. The trial showed that major cardiovascular events were reduced from 12.1% to 9.9% (HR 0.81, 95% CI 0.73-0.90) compared with clopidogrel, with an increase in major bleeding related to noncardiac surgery from 1.8% to 2.4% (HR 1.32, 95% CI 1.03-1.68). 22 Subsequent post hoc analyses of the trial identified 1 subgroup that was harmed by prasugrel (patients with prior transient ischemic attack or stroke) and 2 subgroups for which net benefit was less likely (patients aged > 75 yr and those weighing < 60 kg). The TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) RCT, which evaluated medical therapy with prasugrel among patients with acute coronary syndrome who were not undergoing revascularization, showed no clear benefits compared with clopidogrel. 23 A subgroup analysis of TRILOGY ACS suggested that there may have been benefits of more potent an ti platelet therapy in those with angiographically confirmed coronary artery disease.
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Ticagrelor
The PLATO (Platelet Inhibition and Patient Outcomes) RCT found that ticagrelor significantly reduced major cardiovascular events from 11.7% to 9.8% (HR 0.84, 95% CI 0.77-0.92) compared with clopidogrel, including a significant absolute decrease of 1.1% in vascular mortality. 25 Rates of major bleeding related to non cardiac surgery were increased from 3.8% to 4.5% (HR 1.19, 95% CI 1.02-1.38). Because heterogeneity of ticagrelor effect by geographical region was linked to the ASA dose used concomitantly, it is indicated only in association with low-dose (≤ 100 mg daily) ASA.
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Cangrelor
The recently published CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) PHOENIX RCT evaluated cangrelor, an intravenous direct-acting ADP receptor antagonist with a short half-life. 27 Among patients undergoing PCI who were not taking ADP receptor antagonists, cangrelor re duced major coronary events at 48 hours compared with placebo (5.9% v. 4.7%; odds ratio 0.78, 95% CI 0.66-0.93) without increasing severe bleeding events. A meta-analysis of the 3 CHAMPION trials confirmed these findings, including a reduction in stent thrombosis at 48 hours.
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Recommendations for clinical practice
Among patients with acute coronary syndrome who are not at high risk of bleeding who undergo PCI, either prasugrel or ticagrelor can be used. Ticagrelor decreases vascular mortality, can be used in patients with medically managed acute coronary syndrome and can be given in the emergency department as pretreatment, but it needs to be taken twice daily and can be associated with bradycardia (ventricular pauses > 3 s at 1 wk: 5.8% v. 3.6% with clopidogrel, p = 0.01) and dyspnea (13.8% v. 7.8% with clopidogrel, p < 0.001). 25 Clopidogrel is preferred for patients who are receiving fibrinolytics, and those in need of long-term anticoagulation and at higher risk of bleeding. In many regions, newer agents are not available or costs are increased compared with generic clopidogrel.
What is the current role of glycoprotein IIb/IIIa receptor antagonists?
Use of glycoprotein IIb/IIIa receptor antagonists has declined sharply in the last 5 years with the increasing use of pretreatment with ADP antagonists, the use of bivalirudin (a direct thrombin inhibitor) at the time of PCI and the emerging role of newer molecules. 16, 17, 29 This class of drug, which includes abciximab, eptifibatide and tirofiban, inhibits platelet aggregation by preventing binding of fibrinogen between platelets via the glycoprotein IIb/IIIa receptors. These agents are still indicated for patients who did not receive dual antiplatelet therapy, for patients who have recurrent symptoms despite dual antiplatelet therapy, or at the time of PCI for patients with ST elevation MI who are receiving intravenous unfractionated heparin. Pretreatment with these drugs before primary PCI in ST elevation MI was not associated with benefit in terms of major cardiovascular events and increased bleeding complications. [30] [31] [32] In contemporary practice, they are mostly given at the time of PCI in the event of procedural complications.
What parenteral anticoagulation should be given?
Four agents are commonly used in acute coronary syndrome: unfractionated heparin, enoxaparin, fondaparinux and bivalirudin. The first 3 are indirect agents, whereas bivalirudin is a direct inhibitor of thrombin. Intravenous unfractionated heparin is indicated in all scenarios of acute coronary syndrome, alone or in combination with glycoprotein IIb/IIIa inhibitors, and should be administered when the diagnosis is made. 16, 17, 29 Anticoagulation with medical or thrombolytic therapy Among patients receiving conservative treatment or fibrinolytics, all agents can be used except for bivalirudin, which has not been well studied in these settings (Table 2 33 -38 ). Both enoxaparin (relative risk [RR] 0.83, 95% CI 0.77-0.90) and fondaparinux (RR 0.82, 95% CI 0.66-1.02) when used up to 8 days or until discharge were found to reduce major cardiac events in ST elevation MI compared with unfractionated heparin. 33, 35 An increase in major bleeding was present with enoxaparin (RR 1.53, 95% CI 1.23-1.89). 33 Head-tohead comparison of enoxaparin and fondaparinux was done in non-ST elevation acute coronary syndrome and showed that fondaparinux caused fewer Review Review major bleeding events (HR 0.52, 95% CI 0.44-0.61) without compromising efficacy.
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Anticoagulation with invasive management Among patients receiving early invasive treatment or primary PCI, any of the agents can be considered (Table 2) ; however, fondaparinux when used alone is associated with catheter thrombosis. 34, 35 This phenomenon can be overcome with use of a bolus of unfractionated heparin during the procedure. Because of lack of efficacy and safety in the primary PCI arm of OASIS-6, fondaparinux is not recommended for ST elevation MI managed invasively. 35 Enoxaparin appears to increase major bleeding complications when compared with unfractionated heparin in non-ST elevation acute coronary syndrome, largely related to patients who crossed over arms of treatment during a trial. 36 Finally, bi valirudin was shown to reduce major bleeding episodes (HR 0.59, 95% CI 0.45-0.76) compared with heparin plus glycoprotein IIb/IIIa inhibitors with similar rates of major cardiovascular events. 37, 38 In subgroup analyses, patients who received pretreatment with clopidogrel and unfractionated heparin before angiography tended to have the best results with bivalirudin.
Recommendations for clinical practice
Patients receiving conservative treatment or fibrinolysis should receive either enoxaparin or fondaparinux because of ease of use and comparable efficacy. Data on enoxaparin in ST elevation MI appear to be stronger compared with fondaparinux and use should be encouraged, whereas fondaparinux should be a first option, if available, in non-ST elevation MI over enoxaparin because of its better safety.
Among patients receiving invasive treatment, intravenous unfractionated heparin should be given as soon as the diagnosis is made because this agent can be easily titrated in the catheterization laboratory; it avoids switching between enoxaparin and unfractionated heparin, which can be associated with an increase in bleeding; and it allows for bivalirudin use during PCI at the interventional cardiologist's discretion, based on ischemic and bleeding risk evaluation.
Is there a role for oral anticoagulants after acute coronary syndrome?
Observational studies have shown that duration of anticoagulation was inversely correlated to pres- ence of mural thrombus in anteroapical aneurysms, which is associated with systemic embolization. 39 The addition of warfarin to dual antiplatelet therapy with clopidogrel is still indicated for 3 months after an anterior ST elevation MI with residual apical akinesis based on these data. 17 Substantial progress has been made in the field of oral anticoagulants with new molecules that have more predictable antithrombotic effect and require less monitoring. Dabigatran, an oral direct thrombin inhibitor, has not been evaluated in any large RCT of acute coronary syndrome. Apixaban and rivaroxaban are oral direct factor Xa inhibitors that have been evaluated in acute coronary syndrome (Table 3 40 ,41 ). The trial evaluating full-dose apixaban versus placebo was stopped early owing to a lack of benefit and an increased risk of major bleeding (HR 2.59, 95% CI 1.50-4.46). 40 Very low-dose rivaroxaban (2.5 mg twice daily) given within 7 days of acute coronary syndrome, compared with placebo, decreased the incidence of major cardiac events, including mortality (9.1% v. 10.7%; HR 0.84, 95% CI 0.72-0.97), at the expense of an increase in major bleeding (1.8% v. 0.6%; HR 3.46, 95% CI 2.08-5.77). 41 The 5-mg twicedaily dose was also tested and showed similar results for the ischemic component, but bleeding risk was greater. 41 Besides the recommendation of a short course of warfarin in patients with post-MI apical akinesis, there is no indication for full-dose oral anticoagulation after acute coronary syndrome. Among patients with other indications for anticoagulation such as atrial fibrillation or thromboembolic process, warfarin still appears to be the preferable drug to use because full-dose newer anticoagulants either have no data involving patients receiving dual antiplatelet therapy or are known to increase major bleeding without having an antidote in case of adverse events.
Remaining challenges
Box 2 provides 2 examples of when and how to use antiplatelet agents and anticoagulants in acute coronary syndrome. Although therapeutic options have evolved substantially in recent years, there are still many questions to answer (Box 3). Dual antiplatelet therapy after acute coronary syndrome is indicated for 1 year, but its optimal duration, especially among patients who receive newer-generation drug-eluting stents, is uncertain. [42] [43] [44] [45] [46] Several trials are underway testing shorter and longer durations of dual antiplatelet therapy. [47] [48] [49] Attempts to personalize therapy with the use of platelet function testing or genetic testing to adjust clopidogrel dose have been unsuccessful. 50, 51 Even after controlling for known factors that affect drug metabolism and compliance, variability in clopidogrel response is still large. He was then taken to the catheterization laboratory where angiography performed via the femoral artery showed an occluded left anterior descending coronary artery. A bolus of bivalirudin followed by an infusion was started, and percutaneous coronary intervention of his occluded coronary artery was performed with implantation of a drug-eluting stent without complication. The bivalirudin infusion was stopped at the end of the procedure, and the patient was admitted to hospital for 3 days. He was discharged home with ASA 80 mg daily and ticagrelor 90 mg twice daily, which he will take for 1 year.
Scenario 2:
An 83-year-old woman with a prior stroke and a past episode of gastrointestinal bleeding was brought to the emergency department from her nursing home for shortness of breath and atypical chest discomfort. Her initial electrocardiogram showed T-wave inversion in the inferior leads, and a troponin test came back elevated. Because of her medical comorbidities and hemodynamic stability, conservative medical management was elected for her non-ST elevation myocardial infarction. Her ASA dosage was kept at 80 mg daily, and a first dose of clopidogrel 300 mg was given, followed by 75 mg daily. She received 2.5 mg of subcutaneous fondaparinux throughout her 6-day hospital stay without any recurrence of gastrointestinal bleeding. She was discharged back to her nursing home with ASA 80 mg daily and clopidogrel 75 mg daily for an intended duration of 12 months.
Box 3: Gaps in knowledge
• The optimal duration of dual antiplatelet therapy after acute coronary syndrome is uncertain, especially with the use of newer-generation drugeluting stents. • The role of yet unapproved drugs, such as intravenous adenosine diphosphate receptor antagonists and low-dose oral anticoagulants, is still undefined.
• Defining new factors associated with antiplatelet response has not yet allowed personalization of antiplatelet therapy.
